A randomized, 20 week, double blind, placebo-controlled, parallel-group, multidose multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigoid only, in adult and adolescent patients with seasonal allergic asthma and comorbid seasonal allergic rhinoconjunctivitis
Laufzeit: 01.01.2006 - 31.12.2008
